The Key Level In Gilead Sciences You Need To Watch For

Gilead Sciences, Inc. GILD is scheduled to report its fourth-quarter 2014 financial results on Thursday. Analysts expect the company to deliver earnings of $2.22 per share for the quarter, and $7.92 per share for the whole year. Fourth-quarter revenues are expected to come in at $6.72 billion, up about 115 percent year-over-year, while full-year revenues are projected at $24.3 billion.

Related Link: Gilead Could Miss Earnings (Hint: Watch Drug Sales)

CMT Christian Tharp told Benzinga in an email that, “Over the last 5 months GILD has stalled at its $110 resistance on 3 separate occasions. The one time the stock pushed above that mark it led to a high of almost $117/share. Watch for GILD to possibly break that $110 mark on a well received earnings report. Otherwise, $100 is the key level to monitor on the downside.”

Shares Of Gilead traded recently at $105.22, down 0.9 percent.